The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Novel agent therapies are improving R/R PTCL outcomes
Jia Ruan, MD, PhD, of Weill Cornell Medical College, New York, NY, at the 2018 American Society of Hematology (ASH) Annual Meeting, in San Diego, CA, discusses the many novel agents currently available for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL). Dr Ruan goes on to explain how PTCL is predominantly treated with chemotherapy, which has relatively low remission rates. However, novel agents such as the antibody-drug conjugate brentuximab vedotin, which has an overall response rate of 40-50%, are improving the clinical outcomes of patients with relapsed/refractory PTCL.
